Autism Speaks has released details of the genome sequencing database it is building on Google's cloud platform. The plan is to sequence the whole genomes of 10,000 people in families affected by autism and make the resulting database freely available to researchers.
Welcome to the hall of shame, where blockbuster drug projections go to die. Here you'll find some drugs that clearly should never have wound up in Phase III to begin with, a few that were actually steered back to the clinic in a doomed attempt to mine something positive after wasting millions on clinical trials and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology. Read more >
Hobbled by sliding sales of Advair, GlaxoSmithKline's U.S. group started to chop away at its large organization in North Carolina and Philadelphia on Wednesday as Glaxo's North American chief Deirdre Connelly began to outline exactly where the ax will fall. The company says that the bulk of the job cuts will be made in Research Triangle Park, NC, slashing R&D as it concentrates drug research work in Philadelphia and Stevenage in the U.K. No exact numbers were reported today by GSK, but the company filed a report with the state noting that it is eliminating 900 jobs.
POPULAR COMMENT THREADS
Microsoft co-founder Paul Allen has once again dipped into his personal fortune to advance science. The latest venture sees Allen donate $100 million to create a cell science center with a heavy reliance on IT.
Milestone Venture Partners is readying a digital-health investment fund. The VC shop is aiming to raise $150 million from biopharma companies and others to invest in up to 20 early-stage digital health companies.
One week after striking a deal with Foundation Medicine, Google Ventures-backed cancer analytics firm Flatiron Health has hooked up with Vector Oncology to advance its clinical research and real-world evidence activities.
The 10 biotechs in the latest batch of Y Combinator startups--as well as those that have already graduated from the incubator--will receive $20,000 to spend at Transcriptic's automated life science laboratory.
Pfizer is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members.
A choice bioinformatics position just opened up at Calico. The secretive, Google-backed anti-aging biotech is recruiting a head of bioinformatics to lead the creation of infrastructure and tools for acquiring and processing sequence data.
From Our Sister Sites
Shares of Tetraphase Pharmaceuticals ($TTPH) spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, leaving the company...
A team from Finland has for the first time confirmed a link between GlaxoSmithKline's swine flu vaccine, Pandemrix, and narcolepsy.